0byt3m1n1-V2
Path:
/
home
/
nlpacade
/
www.OLD
/
arcaneoverseas.com
/
79995o83
/
cache
/
[
Home
]
File: f6aed2acd625f557f445851cda2d72bc
a:5:{s:8:"template";s:10119:"<!DOCTYPE html> <html lang="en"> <head> <meta charset="utf-8"/> <title>{{ keyword }}</title> <link href="//fonts.googleapis.com/earlyaccess/notokufiarabic" id="notokufiarabic-css" media="all" rel="stylesheet" type="text/css"/> </head> <style rel="stylesheet" type="text/css">@charset "UTF-8";html{-ms-touch-action:manipulation;touch-action:manipulation;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}footer,header,nav{display:block}a{background-color:transparent}a:active,a:hover{outline-width:0}*{padding:0;margin:0;list-style:none;border:0;outline:0;box-sizing:border-box}:after,:before{box-sizing:border-box}body{background:#f7f7f7;color:#2c2f34;font-family:-apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue","Open Sans",sans-serif;font-size:13px;line-height:21px}a{color:#333;text-decoration:none;transition:.15s}a:hover{color:#08f}::-moz-selection{background:#08f;color:#fff;text-shadow:none}::selection{background:#08f;color:#fff;text-shadow:none}.button.guest-btn:not(:hover){color:#2c2f34}.background-overlay{background-attachment:fixed}.blocks-title-style-4 .widget-title a:not(:hover){color:#fff}.blocks-title-style-7 #tie-wrapper .widget-title a:not(:hover){color:#fff}.blocks-title-style-8 .mag-box .mag-box-title h3 a:not(:hover){color:inherit}.screen-reader-text{clip:rect(1px,1px,1px,1px);position:absolute!important;height:1px;width:1px;overflow:hidden}.autocomplete-suggestions.live-search-dark .post-title a:not(:hover){color:#fff}.autocomplete-suggestions.live-search-light .post-title a:not(:hover){color:#2c2f34}.autocomplete-suggestion.live-search-dark .post-title a:not(:hover){color:#fff}.autocomplete-suggestions.live-search-popup .post-title a:not(:hover){color:#fff}.dark-skin .tie-slider-nav li span:not(:hover){color:#aaa;border-color:rgba(0,0,0,.1)}.pages-nav .next-prev a:not(:hover),.pages-nav .pages-numbers a:not(:hover){color:#2c2f34}#breadcrumb a:not(:hover){color:#999}#main-nav .components>li.social-icons-item .social-link:not(:hover) span,#top-nav .components>li.social-icons-item .social-link:not(:hover) span{color:#2c2f34}ul:not(.solid-social-icons) .social-icons-item a:not(:hover){background-color:transparent!important}a.remove.light-btn:not(:hover):before{color:#fff}.tie-alignleft{float:left}#tie-wrapper,.tie-container{height:100%;min-height:650px}.tie-container{position:relative;overflow:hidden}#tie-wrapper{background:#fff;position:relative;z-index:108;height:100%;margin:0 auto}#content{margin-top:30px}@media (max-width:991px){#content{margin-top:15px}}.site-content{-ms-word-wrap:break-word;word-wrap:break-word}.boxed-layout #tie-wrapper{max-width:1230px}@media (min-width:992px){.boxed-layout #tie-wrapper{width:95%}}#theme-header{background:#fff;position:relative;z-index:999}#theme-header:after{content:"";display:table;clear:both}.logo-row{position:relative}.logo-container{overflow:hidden}#logo{margin-top:40px;margin-bottom:40px;display:block;float:left}#logo a{display:inline-block}@media (max-width:991px){#theme-header #logo{margin:10px 0!important;text-align:left;line-height:1}}.main-nav-dark #main-nav .comp-sub-menu a:not(:hover),.top-nav-dark #top-nav .comp-sub-menu a:not(:hover){color:#fff}.main-nav-dark #main-nav .comp-sub-menu a.checkout-button:not(:hover),.top-nav-dark #top-nav .comp-sub-menu a.checkout-button:not(:hover){color:#fff}.top-nav-dark #top-nav .comp-sub-menu .button.guest-btn:not(:hover){background:#1f2024;border-color:#1f2024}#top-nav a:not(.button):not(:hover){color:#2c2f34}.top-nav-dark #top-nav .breaking a:not(:hover),.top-nav-dark #top-nav .breaking-news-nav a:not(:hover){color:#aaa}.top-nav-dark #top-nav .components>li.social-icons-item .social-link:not(:hover) span{color:#aaa} .main-nav-wrapper{display:none}.main-menu-wrapper .tie-alignleft{width:100%}}.light-skin #mobile-social-icons .social-link:not(:hover) span{color:#777!important}.post-meta a:not(:hover){color:#777}.big-thumb-left-box .posts-items li:first-child .post-meta a:not(:hover),.miscellaneous-box .posts-items li:first-child .post-meta a:not(:hover){color:#fff}.box-dark-skin .mag-box-options .mag-box-filter-links li a:not(:hover),.dark-skin .mag-box .mag-box-options .mag-box-filter-links li a:not(:hover){color:#aaa}.entry-header .post-meta a:not(:hover){color:#333}.single-big-img .post-meta a:not(:hover){color:#fff}.about-author .social-icons li.social-icons-item a:not(:hover) span{color:#2c2f34}.multiple-post-pages a:not(:hover){color:#2c2f34}.post-content-slideshow .tie-slider-nav li span:not(:hover){background-color:transparent}.login-widget .forget-text:not(:hover){color:#2c2f34}.post-tags a:not(:hover),.widget_layered_nav_filters a:not(:hover),.widget_product_tag_cloud a:not(:hover),.widget_tag_cloud a:not(:hover){color:#2c2f34}.dark-skin .latest-tweets-widget .slider-links .tie-slider-nav li span:not(:hover){background-color:transparent}.main-slider .thumb-meta .post-meta a:not(:hover){color:#fff}.main-slider .thumb-meta .post-meta a:not(:hover):hover{opacity:.8}#tie-wrapper:after{position:absolute;z-index:1000;top:-10%;left:-50%;width:0;height:0;background:rgba(0,0,0,.2);content:'';opacity:0;cursor:pointer;transition:opacity .5s,width .1s .5s,height .1s .5s}#footer{margin-top:50px;padding:0}@media (max-width:991px){#footer{margin-top:30px}}#site-info{background:#161619;padding:20px 0;line-height:32px;text-align:center}.dark-skin{background-color:#1f2024;color:#aaa}.dark-skin .pages-nav .next-prev a:not(:hover),.dark-skin .pages-nav .pages-numbers a:not(:hover),.dark-skin .single-big-img .post-meta a:not(:hover),.dark-skin a:not(:hover){color:#fff}.dark-skin #mobile-menu-icon:not(:hover) .menu-text,.dark-skin .about-author .social-icons li.social-icons-item a:not(:hover) span,.dark-skin .login-widget .forget-text:not(:hover),.dark-skin .multiple-post-pages a:not(:hover),.dark-skin .post-meta a:not(:hover){color:#aaa}.dark-skin .latest-tweets-slider-widget .latest-tweets-slider .tie-slider-nav li a:not(:hover){border-color:rgba(255,255,255,.1)}.dark-skin .boxed-five-slides-slider li:not(.slick-active) button:not(:hover),.dark-skin .boxed-four-taller-slider li:not(.slick-active) button:not(:hover),.dark-skin .boxed-slider-three-slides-wrapper li:not(.slick-active) button:not(:hover){background-color:rgba(255,255,255,.1)}.dark-skin .widget a:not(:hover),.dark-skin .widget-title a:not(:hover){color:#fff}.container{margin-right:auto;margin-left:auto;padding-left:15px;padding-right:15px}.container:after,.container:before{content:" ";display:table}.container:after{clear:both}@media (min-width:768px){.container{width:100%}}@media (min-width:992px){.container{width:100%}}@media (min-width:1200px){.container{max-width:1200px}}.tie-row{margin-left:-15px;margin-right:-15px}.tie-row:after,.tie-row:before{content:" ";display:table}.tie-row:after{clear:both}.tie-col-md-12,.tie-col-md-4{position:relative;min-height:1px;padding-left:15px;padding-right:15px}@media (min-width:992px){.tie-col-md-12,.tie-col-md-4{float:left}.tie-col-md-4{width:33.33333%}.tie-col-md-12{width:100%}} .fa{display:inline-block;font:normal normal normal 14px/1 FontAwesome;font-size:inherit;text-rendering:auto;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}.fa-align-left:before{content:"\f036"}@media print{body,html{background-color:#fff;color:#000;margin:0;padding:0}li,ul{page-break-inside:avoid}.single-big-img .entry-header .post-meta a:not(:hover){color:#000;text-shadow:unset}}body{visibility:visible!important}@media (min-width:992px){.tie-col-md-12,.tie-col-md-4{float:right}}.tie-alignleft{float:right}html{direction:rtl}#logo{float:right}@media (min-width:992px){.main-menu,.main-menu ul li{float:right}#theme-header .menu li.menu-item-has-children>a:before{left:12px;right:auto}}@media (max-width:991px){#theme-header #logo{text-align:right}}</style> <body class="rtl boxed-layout blocks-title-style-1 magazine1 is-thumb-overlay-disabled is-desktop is-header-layout-3 full-width hide_share_post_top hide_share_post_bottom wpb-js-composer js-comp-ver-5.1 vc_responsive" id="tie-body"> <div class="background-overlay"> <div class="site tie-container" id="tie-container"> <div id="tie-wrapper"> <header class="header-layout-3 main-nav-dark main-nav-below main-nav-boxed mobile-header-default" id="theme-header"> <div class="container"> <div class="tie-row logo-row"> <div class="logo-wrapper"> <div class="tie-col-md-4 logo-container"> <div id="logo" style="margin-top: 20px; margin-bottom: 20px;"> <a href="#" title="ADD"> {{ keyword }} </a> </div> </div> </div> </div> </div> <div class="main-nav-wrapper"> <nav class="" id="main-nav"> <div class="container"> <div class="main-menu-wrapper"> <div id="menu-components-wrap"> <div class="main-menu main-menu-wrap tie-alignleft"> <div class="main-menu" id="main-nav-menu"><ul class="menu" id="menu-tielabs-main-single-menu" role="menubar"><li aria-expanded="false" aria-haspopup="true" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-975 menu-item-has-icon is-icon-only" id="menu-item-975" tabindex="0"><a href="#"> <span aria-hidden="true" class="fa fa-align-left"></span> <span class="screen-reader-text"></span></a> <ul class="sub-menu menu-sub-content"> <li class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-1039" id="menu-item-1039"><a href="#">Home</a></li> <li class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-1040" id="menu-item-1040"><a href="#">About</a></li> <li class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-1041" id="menu-item-1041"><a href="#">Contacts</a></li> </ul> </li> </ul></div> </div> </div> </div> </div> </nav> </div> </header> <div class="site-content container" id="content"> <div class="tie-row main-content-row"> {{ text }} <br> {{ links }} </div> </div> <footer class="site-footer dark-skin" id="footer"> <div class="" id="site-info"> <div class="container"> <div class="tie-row"> <div class="tie-col-md-12"> {{ keyword }} 2021 </div> </div> </div> </div> </footer> </div> </div> </div> </body> </html>";s:4:"text";s:5796:"Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Accomplishments and Strategy for 2021, Atossa Therapeutics Announces Two-Year Update of FDA-Approved Expanded Access Treatment with Endoxifen, Atossa Therapeutics’ Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study to be Halted Early. Copyright © 2021 Atossa Therapeutics, Inc. All Rights Reserved. SOS Ltd. Tenax Therapeutics Inc. TENX 2.69 0.09 (3.24%). Since the … The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. Atossa Therapeutics, Inc. Common Stock (ATOS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. At the end of 2018, the FDA authorized a single-patient study under its Expanded Access, or compassionate use program, for this breast cancer patient to receive Atossa's oral Endoxifen in the "window of opportunity" between diagnosis of breast cancer and surgery. Description: Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in the US. Shares of Atossa Therapeutics (ATOS) have done what shares of most companies in the hunt for coronavirus solutions have done in 2020 – appreciate. High volatility in Atossa Genetics Inc. stock price on Monday which ended trading at $3.86 (Updated on February 08, 2021) Buy or Hold candidate since 2021-01-13 Gain 227.12% PDF. The only place for free North American stock rankings incorporating insider commitment. Home of the insider insights newsletter and the Canadian Insider Club which offers alerts and premium research. Atossa Therapeutics Breast Cancer Drug Shows Overwhelmingly Positive Results, FDA Halts Study Early in Order to Start Clinical Development Yesterday ATOS drug was cleared from the Phase 2 FDA study because the results were so freaking overwhelmingly good. The only place for free North American stock rankings incorporating insider commitment. Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of … "We are very encouraged by this patient's experience with our Endoxifen over the past two years. During the day the stock fluctuated 10.14% from a day low at $3.65 to a day high of … Home of the insider insights newsletter and the Canadian Insider Club which offers alerts and premium research. We work with organizations throughout the world to move our programs forward in an efficient and cost-effective manner. SEATTLE, June 11, 2020 -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of. SEATTLE, Dec. 17, 2020 -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the "Company" or "Atossa"), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced today that it has entered into a securities purchase … December 17, 2020 - 9:15 am. Company Contact:Atossa Therapeutics, Inc.Kyle Guse, CFO and General CounselOffice: 866 893-4927kyle.guse@atossainc.com, Investor Relations Contact:Core IROffice:(516) 222-2560ir@atossainc.com. Atossa has two programs to develop therapies to treat COVID-19: One called the COVID-19 HOPE Program which uses AT-H201 for severely ill patients to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators and another called AT-301 Nasal Spray for at-home use immediately following diagnosis of COVID-19 to proactively reduce symptoms of COVID-19 and to slow the infection rate so that a person’s immune system can more effectively fight the virus. We respect your email privacy. "To date, the patient has not had a recurrence of breast cancer, as assessed by clinical breast examination and mammography; has not had treatment-related changes in periodic laboratory blood tests and general clinical examinations; and, the treatment has been well tolerated, including an absence of typical vasomotor symptoms commonly associated with tamoxifen (for example, night sweats and hot flashes), an FDA-approved drug frequently prescribed for breast cancer treatment," commented Sidney Goldblatt, M.D., Principal Investigator. Latest ATOS Atossa Therapeutics Inc News Live. We need to get the stock known so we can get the push we need comment it in places or show them the potential at it , if we look at the graph right now it is primed for a cup and handle move , in FEB 2 we have news coming so if we can get this in a uptrend today the stock is gonna go parabolic it's oversold and undervalued right now so buy more and hold, TO THE MOON BOYS Unsubscribe any time. Pre-Market 0.01 (0.37%) Get stock quotes, news, fundamentals and easy to read SEC and SEDI insider filings. Get stock quotes, news, fundamentals and easy to read SEC and SEDI insider filings. SEATTLE, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the "Company" or "Atossa"), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced today that it has entered into a … We use cookies on our website to enhance the user experience. Get stock quotes, news, fundamentals and easy to read SEC and SEDI insider filings. We use cookies to ensure that we give you the best experience on our website. Real-time trade and investing ideas on Digital Ally Inc. DGLY from the largest community of traders and investors. ";s:7:"keyword";s:30:"atossa therapeutics stocktwits";s:5:"links";s:930:"<a href="http://arcaneoverseas.com/79995o83/sweet-baby-ray%27s-wing-sauces-e286bb">Sweet Baby Ray's Wing Sauces</a>, <a href="http://arcaneoverseas.com/79995o83/traditional-hawaiian-blessing-e286bb">Traditional Hawaiian Blessing</a>, <a href="http://arcaneoverseas.com/79995o83/why-georgetown-law-essay-e286bb">Why Georgetown Law Essay</a>, <a href="http://arcaneoverseas.com/79995o83/pickled-ginger-near-me-e286bb">Pickled Ginger Near Me</a>, <a href="http://arcaneoverseas.com/79995o83/shell-change-oil-price-philippines-2020-e286bb">Shell Change Oil Price Philippines 2020</a>, <a href="http://arcaneoverseas.com/79995o83/10k-relocation-package-e286bb">10k Relocation Package</a>, <a href="http://arcaneoverseas.com/79995o83/cardioid-vs-supercardioid-for-live-vocals-e286bb">Cardioid Vs Supercardioid For Live Vocals</a>, <a href="http://arcaneoverseas.com/79995o83/maynard%27s-margate-menu-e286bb">Maynard's Margate Menu</a>, ";s:7:"expired";i:-1;}
©
2018.